Drug or treatment

Asciminib clinical trials

• 18Clinical trials
• 34Countries

Newest trials

All recruiting trials (18)

• Asciminib for chronic phase CML with T315I mutation

  This study tests asciminib 200 mg twice daily in adults with chronic phase CML and a T315I mutation after stem cell transplant to see if it helps control leukemia.

  Recruiting at 5 sites Phase 2 University of Jena · Aachen and 9 other locations · NCT07789574

• Asciminib for Ph+ CML-CP in Germany: real-world patient experiences

  This real-world study tests how asciminib performs in adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, including those newly diagnosed or after one prior TKI.

  Recruiting at 74 sites Novartis · Baden-Baden, Baden-Wurttemberg and 73 other locations · NCT07549516

• Asciminib in children and young adults with relapsed or refractory Ph+ or ABL-class Ph-like ALL

  This study tests asciminib in kids and young adults with relapsed or refractory Philadelphia-positive or ABL-class Ph-like ALL to see if it is safe and helps treat the leukemia.

  Recruiting at 4 sites Phase 1/2 Novartis · Sydney, New South Wales and 3 other locations · NCT07387926

• Scemblix (asciminib) for newly diagnosed chronic-phase CML in China

  This project will try asciminib (Scemblix) in adults newly diagnosed with chronic-phase CML to see if it controls the disease and is safe.

  Recruiting Novartis · Wuhan, Hubei · NCT07375355

• Asciminib for children and teens with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase

  This study will try asciminib as a treatment for children aged 1 to under 18 with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase, including newly diagnosed patients and those who are resistant or intolerant to prior TKIs, with or without the T315I mutation.

  Recruiting at 39 sites Phase 2 Novartis · Chicago, Illinois and 38 other locations · NCT07354074

• Asciminib maintenance after alloHCT or CAR T for adults with Ph+ ALL

  Doctors will try asciminib in adults with Ph+ ALL who are in remission after an allogeneic stem cell transplant or CAR T therapy to check safety and find the best dose to help prevent relapse.

  Recruiting Phase 1 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07250087

• Asciminib plus trastuzumab for HER2+ breast cancer with brain metastases

  A study tests whether adding asciminib to trastuzumab can help people with HER2-positive breast cancer that has spread to the brain.

  Recruiting Phase 1/2 Duke University · Durham, North Carolina · NCT07136428

• Asciminib as maintenance after cellular therapies for Ph+ ALL

  This phase 1 study tests whether maintenance with asciminib is safe and tolerable for adults with Philadelphia chromosome–positive ALL after HSCT or CAR-T therapy.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT07040982

• Observational study on the effectiveness of asciminib for chronic myelogenous leukemia in Saudi Arabia

  This study is testing how well the drug asciminib works for people in Saudi Arabia with chronic myelogenous leukemia who have already tried other treatments.

  Recruiting at 4 sites Novartis · Dammam and 3 other locations · NCT06684964

• Using asciminib for treating chronic myeloid leukemia after prior therapy

  This study is testing if a new drug called asciminib can help people with chronic myeloid leukemia who have already tried one other treatment to see if it improves their condition.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06629584

• Using asciminib to treat chronic myeloid leukemia patients with a specific mutation

  This study is testing if a new drug called asciminib can help people with chronic myeloid leukemia who have a specific mutation and haven't had success with other treatments.

  Recruiting at 6 sites Phase 2 Novartis · Bordeaux and 5 other locations · NCT06514534

• Potential of asciminib in early chronic‑phase CML

  This trial will see if asciminib alone, or asciminib plus nilotinib, helps adults newly diagnosed with chronic‑phase, BCR‑ABL–positive CML reach deep molecular responses and remain off treatment.

  Recruiting at 11 sites Phase 2 Gruppo Italiano Malattie EMatologiche dell'Adulto · Barcelona and 10 other locations · NCT06409936

• Treatment-free remission with asciminib plus TKIs in chronic-phase chronic myeloid leukemia

  This trial tests whether adding asciminib to ongoing TKI therapy helps people with chronic-phase CML who lost remission after stopping TKIs regain and sustain a deeper molecular response so they can attempt stopping treatment again.

  Recruiting Phase 2 Korean Society of Hematology · Incheon, Incheon · NCT06368414

• Combining blinatumomab and asciminib for treating a type of leukemia

  This study is testing if combining two drugs, blinatumomab and asciminib, can help people with a specific type of leukemia feel better and improve their chances of recovery.

  Recruiting at 2 sites Phase 1/2 M.D. Anderson Cancer Center · The Bronx, New York and 1 other locations · NCT06308588

• Evaluating asciminib for newly diagnosed chronic myeloid leukemia patients

  This study is testing a new drug called asciminib to see if it helps people with newly diagnosed chronic myeloid leukemia feel better and achieve a good response to treatment after a year.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06236724

• Observational study of Asciminib in patients with Chronic Myeloid Leukemia

  This study is looking at how well Asciminib works and how safe it is for adults with Chronic Myeloid Leukemia in Korea who are using this medication as prescribed by their doctors.

  Recruiting at 17 sites Novartis · Wŏnju, Gangwon-do and 16 other locations · NCT05943522

• Long-term safety treatment for chronic myelogenous leukemia patients

  This study is testing the long-term safety of a medication called asciminib for patients with chronic myelogenous leukemia who have already been part of another study.

  Recruiting at 61 sites Phase 4 Novartis · Ann Arbor, Michigan and 87 other locations · NCT04877522

• Treatment-free remission for chronic myeloid leukemia after combination therapy

  This study is testing if a combination of two treatments can help people with chronic myeloid leukemia stay in remission without needing more medication after stopping their previous treatment.

  Recruiting at 5 sites Phase 2 Medical College of Wisconsin · Detroit, Michigan and 4 other locations · NCT04838041

Quick answers

How many clinical trials of Asciminib are recruiting right now?

18, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 34 countries. The most sites are in United States (9 trials), South Korea (5 trials), Germany (4 trials), France (3 trials), China (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 8, Phase 1/2: 3, Phase 1: 2, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →